TY - JOUR
T1 - Colony-forming unit cell (CFU-C) assays at diagnosis
T2 - CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R
AU - Li, Bing
AU - Liu, Jinqin
AU - Qu, Shiqiang
AU - Gale, Robert Peter
AU - Song, Zhen
AU - Xing, Ruixian
AU - Liu, Junxia
AU - Ren, Yansong
AU - Xu, Zefeng
AU - Qin, Tiejun
AU - Zhang, Yue
AU - Fang, Liwei
AU - Zhang, Hongli
AU - Pan, Lijuan
AU - Hu, Naibo
AU - Cai, Wenyu
AU - Zhang, Peihong
AU - Huang, Gang
AU - Xiao, Zhijian
N1 - Funding Information:
Supported in part by National Natural Science Funds (No. 81470295, No. 81470297, No. 81370611, No. 81530008), and National Key Technology R&D Program (No. 2014BAI09B13). RPG acknowledges support from the NIHR Biomedical Research Centre funding scheme.
Publisher Copyright:
© 2016, Oncotarget.
PY - 2016
Y1 - 2016
N2 - Background: In vitro colony-forming unit cell (CFU-C) assays are usually-used to detect the quantitative and qualitative features of haematopoietic stem cells (HSCs). We studies CFU-C assays in bone marrow samples from 365 consecutive subjects with newly-diagnosed myelodysplastic syndrome (MDS). Data were interrogated for associations with prognosis. Methods: CFU-C assays were performed according to the protocol of MethoCultTM H4435 Enriched. 365 consecutive newly-diagnosed, untreated subjects with MDS diagnosed from July, 2007 to April, 2014 were studied. All subjects were reclassified according to the 2008 WHO criteria. Subjects were observed for survival until July 31, 2015. Follow-up data were available for 289 (80%) subjects. Median follow-up of survivors was 22 months (range, 1-85) months. Erythroid and myeloid colonies were isolated from each subject with one cytogenetic abnormality such as del(5/5q), +8, del(7/7q) or del(20q). Cytogenetic abnormalities of each colony were analyzed by fluorescence in situ hybridization (FISH). SPSS 17.0 software was used to make statistical analysis. Results: The numbers of burst-forming units-erythroid (BFU-E), colony forming unit-erythroid (CFU-E) and colony forming unit-granulocytes/macrophages (CFUG/M) were significantly lower than normals. A high ratio of cluster- to CFU-G/M was associated with poor-risk cytogenetics. In multivariable analyses a cluster- to CFUG/M ratio > 0.6 was an independent risk-factor for OS after adjusting for IPSS-R (HR 3.339, [95%CI 1.434-7.778]; P = 0.005) in very high-risk cohort.
AB - Background: In vitro colony-forming unit cell (CFU-C) assays are usually-used to detect the quantitative and qualitative features of haematopoietic stem cells (HSCs). We studies CFU-C assays in bone marrow samples from 365 consecutive subjects with newly-diagnosed myelodysplastic syndrome (MDS). Data were interrogated for associations with prognosis. Methods: CFU-C assays were performed according to the protocol of MethoCultTM H4435 Enriched. 365 consecutive newly-diagnosed, untreated subjects with MDS diagnosed from July, 2007 to April, 2014 were studied. All subjects were reclassified according to the 2008 WHO criteria. Subjects were observed for survival until July 31, 2015. Follow-up data were available for 289 (80%) subjects. Median follow-up of survivors was 22 months (range, 1-85) months. Erythroid and myeloid colonies were isolated from each subject with one cytogenetic abnormality such as del(5/5q), +8, del(7/7q) or del(20q). Cytogenetic abnormalities of each colony were analyzed by fluorescence in situ hybridization (FISH). SPSS 17.0 software was used to make statistical analysis. Results: The numbers of burst-forming units-erythroid (BFU-E), colony forming unit-erythroid (CFU-E) and colony forming unit-granulocytes/macrophages (CFUG/M) were significantly lower than normals. A high ratio of cluster- to CFU-G/M was associated with poor-risk cytogenetics. In multivariable analyses a cluster- to CFUG/M ratio > 0.6 was an independent risk-factor for OS after adjusting for IPSS-R (HR 3.339, [95%CI 1.434-7.778]; P = 0.005) in very high-risk cohort.
KW - Colony-forming unit cell
KW - Myelodysplastic syndromes
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85042463703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042463703&partnerID=8YFLogxK
U2 - 10.18632/ONCOTARGET.12105
DO - 10.18632/ONCOTARGET.12105
M3 - Article
C2 - 27655727
AN - SCOPUS:85042463703
SN - 1949-2553
VL - 7
SP - 68023
EP - 68032
JO - Oncotarget
JF - Oncotarget
IS - 42
ER -